Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Wednesday, 31 January 2018

Change in the Number of Shares and Votes in Immunicum

Immunicum AB    

Published: 08:00 CET 31-01-2018 /GlobeNewswire /Source: Immunicum AB / : IMMU /ISIN: SE0005003654

Change in the Number of Shares and Votes in Immunicum

Press Release

31 January 2018

Change in the Number of Shares and Votes in Immunicum

Immunicum AB (publ; IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid tumors ("Immunicum" or the "Company"), today announced that the number of shares and votes in Immunicum as per 31 January 2018 amounts to 50,958,531.

The number of shares and votes in Immunicum has, as a result of a rights issue of shares, increased with 24,999,990, from 25,958,541 to 50,958,531. As per 31 January 2018, there is thus 50,958,531 registered shares and votes in the Company and the share capital amounts to SEK 2,547,926.55. The quotient value per share is accordingly unchanged at SEK 0.05. Immunicum does not hold any own shares.

 

The information is such information that Immunicum is obliged to make public pursuant to Financial Instruments Trading Act. The information was released for public disclosure through the contact persons detailed below on 31 January 2018 at 8.00 am CET.

 

For more information, please contact:

Carlos de Sousa, CEO, Immunicum

Telephone: +46 (0) 31 41 50 52

E-mail: info@immunicum.com

Investor Relations Sweden

Helena Stångberg

Hallvarsson & Halvarsson

Telephone: +46 709 71 12 53

E-mail: ir@immunicum.com  

Investor and Media Relations EU/US

Gretchen Schweitzer and Joanne Tudorica

Trophic Communications

Telephone: +49 172 861 8540

E-mail: ir@immunicum.com  

 

 

 

About Immunicum AB (publ)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com

 

 

 



20180131_Immunicum_Change in Shares and Votes_EN



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Immunicum AB, Grafiska vägen 2, Gothenburg SE-412 63, Sweden
If you would like to unsubscribe and stop receiving these e-mails click here.